Stiris Research Inc. Awarded Phase II Amyotrophic Lateral Sclerosis Trial

Cambridge, MA | London, ON — May 12th, 2023 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the award of a Phase II Amyotrophic lateral sclerosis (ALS) study.

“We are excited to be part of the expansion of this Phase II study in Amyotrophic Lateral Sclerosis (ALS). The hope for this research is to have an overall effect on functional impairment.  Having more clinical trials available helps us support our community by providing options to those with ALS.” said Shantal Feltham, President & CEO.

Amyotrophic lateral sclerosis (ALS), is a rare neurological disease that affects motor neurons—those nerve cells in the brain and spinal cord that control voluntary muscle movement. Voluntary muscles are those we choose to move to produce movements like chewing, walking, and talking. Nearly all cases of ALS are considered sporadic. This means the disease seems to occur at random with no clearly associated risk factors and no family history of the disease. Although family members of people with sporadic ALS are at an increased risk for the disease, the overall risk is very low and most will not develop ALS. (,chewing%2C%20walking%2C%20and%20talking

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.